O	0	5	Light
O	6	15	treatment
O	16	24	prevents
B-condition	25	32	fatigue
O	33	35	in
O	36	41	women
O	42	52	undergoing
O	53	65	chemotherapy
O	66	69	for
O	70	76	breast
O	77	83	cancer
O	83	84	.

O	85	92	Fatigue
O	93	95	is
O	96	99	one
O	100	102	of
O	103	106	the
O	107	111	most
O	112	122	disturbing
O	123	133	complaints
O	134	136	of
O	137	143	cancer
O	144	152	patients
O	153	156	and
O	157	159	is
O	160	165	often
O	166	169	the
O	170	176	reason
O	177	180	for
O	181	194	discontinuing
O	195	204	treatment
O	204	205	.

O	206	210	This
O	211	221	randomized
O	222	232	controlled
O	233	238	study
O	239	245	tested
O	246	249	the
O	250	260	hypothesis
O	261	265	that
O	266	275	increased
O	276	283	morning
O	284	290	bright
O	291	296	light
O	296	297	,
O	298	306	compared
O	307	309	to
O	310	313	dim
O	314	319	light
O	319	320	,
O	321	326	would
O	327	333	result
O	334	336	in
O	337	341	less
O	342	349	fatigue
O	350	352	in
B-eligibility	353	358	women
I-eligibility	359	363	with
I-eligibility	364	370	breast
I-eligibility	371	377	cancer
I-eligibility	378	388	undergoing
I-eligibility	389	401	chemotherapy
O	401	402	.

B-total-participants	403	409	Thirty
I-total-participants	409	410	-
I-total-participants	410	414	nine
O	415	420	women
O	421	426	newly
O	427	436	diagnosed
O	437	441	with
O	442	447	stage
O	448	449	I
O	449	450	-
O	450	453	III
O	454	460	breast
O	461	467	cancer
O	468	472	were
O	473	483	randomized
O	484	486	to
O	487	493	either
B-intervention	494	500	bright
I-intervention	501	506	white
I-intervention	507	512	light
I-intervention	513	514	(
I-intervention	514	517	BWL
I-intervention	517	518	)
O	519	521	or
B-control	522	525	dim
I-control	526	529	red
I-control	530	535	light
I-control	536	537	(
I-control	537	540	DRL
I-control	540	541	)
O	542	551	treatment
O	552	555	and
O	556	560	were
O	561	571	instructed
O	572	574	to
O	575	578	use
O	579	582	the
O	583	588	light
O	589	592	box
O	593	596	for
O	597	599	30
O	600	603	min
O	604	609	every
O	610	617	morning
O	618	628	throughout
O	629	632	the
O	633	638	first
O	639	643	four
O	644	650	cycles
O	651	653	of
O	654	666	chemotherapy
O	666	667	.

O	668	671	The
O	672	688	Multidimensional
O	689	696	Fatigue
O	697	704	Symptom
O	705	714	Inventory
O	715	718	was
O	719	731	administered
O	732	737	prior
O	738	740	to
O	741	744	the
O	745	750	start
O	751	753	of
O	754	766	chemotherapy
O	767	768	(
O	768	776	baseline
O	776	777	)
O	777	778	,
O	779	785	during
O	786	789	the
O	790	802	chemotherapy
O	803	812	treatment
O	813	817	week
O	818	820	of
O	821	826	cycle
O	827	828	1
O	829	830	(
O	830	834	C1TW
O	834	835	)
O	835	836	,
O	837	840	the
O	841	845	last
O	846	850	week
O	851	852	(
O	852	860	recovery
O	861	865	week
O	865	866	)
O	867	869	of
O	870	875	cycle
O	876	877	1
O	878	879	(
O	879	883	C1RW
O	883	884	)
O	884	885	,
O	886	889	the
O	890	902	chemotherapy
O	903	912	treatment
O	913	917	week
O	918	920	of
O	921	926	cycle
O	927	928	4
O	929	930	(
O	930	934	C4TW
O	934	935	)
O	935	936	,
O	937	940	and
O	941	944	the
O	945	949	last
O	950	954	week
O	955	956	(
O	956	964	recovery
O	965	969	week
O	969	970	)
O	971	973	of
O	974	979	cycle
O	980	981	4
O	982	983	(
O	983	987	C4RW
O	987	988	)
O	988	989	.

O	990	993	The
O	994	997	DRL
O	998	1003	group
O	1004	1012	reported
O	1013	1022	increased
B-outcome	1023	1030	fatigue
O	1031	1033	at
O	1034	1038	C1TW
O	1039	1040	(
O	1040	1041	p
O	1042	1043	=
O	1044	1045	0
O	1045	1046	.
O	1046	1049	003
O	1049	1050	)
O	1051	1054	and
O	1055	1059	C4TW
O	1060	1061	(
O	1061	1062	p
O	1063	1064	<
O	1065	1066	0
O	1066	1067	.
O	1067	1070	001
O	1070	1071	)
O	1072	1080	compared
O	1081	1083	to
O	1084	1092	baseline
O	1092	1093	,
O	1094	1099	while
O	1100	1105	there
O	1106	1109	was
O	1110	1112	no
O	1113	1124	significant
O	1125	1131	change
O	1132	1136	from
O	1137	1145	baseline
O	1146	1148	in
O	1149	1152	the
O	1153	1156	BWL
O	1157	1162	group
O	1162	1163	.

O	1164	1165	A
O	1166	1175	secondary
O	1176	1184	analysis
O	1185	1191	showed
O	1192	1196	that
O	1197	1200	the
O	1201	1210	increases
O	1211	1213	in
B-outcome	1214	1221	fatigue
I-outcome	1222	1228	levels
O	1229	1231	in
O	1232	1235	the
O	1236	1239	DRL
O	1240	1245	group
O	1246	1250	were
O	1251	1254	not
O	1255	1263	mediated
O	1264	1271	through
O	1272	1275	nor
O	1276	1286	associated
O	1287	1291	with
O	1292	1299	changes
O	1300	1302	in
O	1303	1308	sleep
O	1309	1311	or
O	1312	1314	in
O	1315	1324	circadian
O	1325	1332	rhythms
O	1333	1335	as
O	1336	1344	measured
O	1345	1349	with
O	1350	1355	wrist
O	1356	1366	actigraphy
O	1366	1367	.

O	1368	1371	The
O	1372	1379	results
O	1380	1382	of
O	1383	1387	this
O	1388	1393	study
O	1394	1401	suggest
O	1402	1406	that
O	1407	1414	morning
O	1415	1421	bright
O	1422	1427	light
O	1428	1437	treatment
O	1438	1441	may
O	1442	1449	prevent
O	1450	1457	overall
O	1458	1465	fatigue
O	1466	1470	from
O	1471	1480	worsening
O	1481	1487	during
O	1488	1500	chemotherapy
O	1500	1501	.

O	1502	1510	Although
O	1511	1514	our
O	1515	1525	hypothesis
O	1526	1530	that
O	1531	1538	overall
O	1539	1546	fatigue
O	1547	1552	would
O	1553	1560	improve
O	1561	1565	with
O	1566	1572	bright
O	1573	1578	light
O	1579	1588	treatment
O	1589	1592	was
O	1593	1596	not
O	1597	1606	supported
O	1606	1607	,
O	1608	1611	the
O	1612	1616	lack
O	1617	1619	of
O	1620	1633	deterioration
O	1634	1636	in
O	1637	1642	total
O	1643	1650	fatigue
O	1651	1657	scores
O	1658	1666	suggests
O	1667	1671	that
O	1672	1678	bright
O	1679	1686	morning
O	1687	1692	light
O	1693	1696	may
O	1697	1699	be
O	1700	1701	a
O	1702	1708	useful
O	1709	1721	intervention
O	1722	1728	during
O	1729	1741	chemotherapy
O	1742	1745	for
O	1746	1752	breast
O	1753	1759	cancer
O	1759	1760	.
